Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 13
Treatment-assignment count: 0
Stratification count: 0
gastric cancer · Monoclonal Antibody
PD-L1 expression is flagged as manual review required because public trials show inclusion required evidence in 21 contexts. FDA CDx context exists. Threshold text varies across public records.
Strongest role: Inclusion Required
Inclusion-required count: 13
Treatment-assignment count: 0
Stratification count: 0
Threshold count: 20
Common snippets: HER2-low | dMMR | dMMR
Threshold label: Fragmented
CDx label: Fda Cdx Context Exists
CDx maturity score: 5/5
Confidence: Low
Signal count: 1
Recent signals: 1
Density label: Low
https://clinicaltrials.gov/study/NCT05216237 | https://clinicaltrials.gov/study/NCT07334431 | https://clinicaltrials.gov/study/NCT07529613 | https://clinicaltrials.gov/study/NCT05608785 | https://clinicaltrials.gov/study/NCT06098898 | https://clinicaltrials.gov/study/NCT06468280 | https://clinicaltrials.gov/study/NCT04744649 | https://clinicaltrials.gov/study/NCT06329973 | https://clinicaltrials.gov/study/NCT05468138 | https://clinicaltrials.gov/study/NCT04030260 | https://clinicaltrials.gov/study/NCT06099821 | https://clinicaltrials.gov/study/NCT07581574 | https://clinicaltrials.gov/study/NCT05104567 | https://clinicaltrials.gov/study/NCT04082364 | https://clinicaltrials.gov/study/NCT07127822 | https://clinicaltrials.gov/study/NCT05594381 | https://clinicaltrials.gov/study/NCT04006821 | https://clinicaltrials.gov/study/NCT04098796 | https://clinicaltrials.gov/study/NCT06881017 | https://clinicaltrials.gov/study/NCT07000253 | https://clinicaltrials.gov/study/NCT04495296